



Wisconsin
CHAPTER

THE WISCONSIN CHAPTER ACC ALONG WITH AstraZeneca PHARMACEUTICALS, LP PRESENTS A NON-CME VIRTUAL PRESENTATION

Clinical Considerations in Stroke or Transient Ischemic Attack

Wednesday, December 2, 2020 | 6:00 PM – 7:00 PM

**Speaker: Joseph Ghobrial, MD, Master of Science,
Senior Medical Science Liaison, AstraZeneca Medical Affairs**

The program is free but you must register

[REGISTRATION LINK](#)

[or wcacc.org](http://wcacc.org)

OBJECTIVES

- Understand the disease burden and pathophysiology for acute ischemic stroke (AIS) and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk transient ischemic attack (TIA).
- Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y₁₂ inhibitor use in this patient population
- Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial